Category: pathway

administration, analysis, analytics, business, Business Analysis, cannabis, cbd, compliance, Concentrates & Extracts, consumer, cultivation, Cultivation & Growing, dea, Dispensaries & Retail, dispensary, drug, Edibles & Processing, extraction, farm bill, FDA, Federal, food, framework, government, growing, industry, law, legal, legalization, legalize, legislation, license, marijuana, market, medical, medicine, Operations, pathway, product, products, Quality, recreational, regulation, regulations, regulatory, safety, state, test, USDA

FDA Punts on CBD Rules

FDA Punts on CBD Rules

On December 20, 2018, Former President Trump signed the Farm Bill into law, which removed hemp-derived cannabidiol (CBD) from the Controlled Substances […]

1, analysis, analytics, and Cosmetics Act, application, approval, approve, business, Business Analysis, cannabidiol, cannabis, cbd, clinical, clinical trials, compliance, consumer packaged goods, CPG, CSA, dea, derived, deschedule, descheduled, Dravet syndrome, drug, Drug Enforcement Administration, Epidiolex, epilepsy, extraction, FDA, FDCA, Federal, Federal Food, FFDCA, food and drug administration, formulation, government, GW, GW Pharma, hemp, industry, law, legal, legalization, legalize, legislation, Lennox-Gastaut syndrome, license, marijuana, market, medical, medicine, New, patent, pathway, patient, pharma, pharmaceutical, product, Product Development, program, regulation, regulations, regulatory, REMS, safety, schedule, seizures, state, Substances, thc, trial, TSC

How GW Pharma Won CBD

How GW Pharma Won CBD

As of this writing, the United States Food and Drug Administration (FDA) has approved GW Pharma’s CBD drug Epidiolex for treating profound […]